Cerevance, a Boston-based developer of precision CNS therapies, has raised $20 million in an oversubscribed Series C funding round from existing investors including Google Ventures and Gates Frontier. The company uses its proprietary NETSseq platform, which profiles over 16,000 human brain samples, to identify novel targets for neurodegenerative and psychiatric disorders. The capital extends its runway into mid-2027, supporting operations through topline data from the Phase 3 ARISE trial of lead candidate solengepras expected in Q3 2026.
Parkinson's Funding Wave Accelerates
The raise aligns with heightened investor interest in Parkinson's innovation. Vima Therapeutics raised $40M Series A extension in March 2026 to expand its oral therapy into Parkinson's studies, while NRG Therapeutics secured further £50M funding in January 2026 from Parkinson's UK. Cerevance's focus on non-dopaminergic mechanisms via human brain-derived data positions it amid this momentum, as FDA scrutiny on levodopa seizure risks underscores the need for alternatives per Reuters.
OFF Time Burdens Advanced Parkinson's
Motor fluctuations, particularly OFF periods, affect advanced Parkinson's patients on levodopa, disrupting daily activities. Solengepras aims to reduce these OFF episodes as an adjunct therapy. The ARISE trial enrolled 341 patients across the US, Europe, UK, and Australia to evaluate this per BioSpace.
NETSseq Unlocks Neuron-Specific Targets
Cerevance's NETSseq platform, licensed from Rockefeller University, generates the largest cell-type specific human brain multi-omics dataset from over 16,000 samples. This enabled discovery of GPR6, targeted by solengepras (CVN424), a first-in-class inverse agonist normalizing overactive indirect pathways without dopaminergic side effects. Phase 2 data showed a 1.73-hour reduction in daily OFF time per company pipeline.
As CEO Craig Thompson noted:
"This is a critical moment for Cerevance."
The pipeline extends to CVN766 for schizophrenia and binge eating, and CVN293 for ALS, Alzheimer's, and FTD neuroinflammation, with Phase 1 complete for both.
Existing Investors Signal Confidence
The oversubscribed round drew solely from prior backers like Double Point Ventures, Lightstone Ventures, and UPMC, bringing total funding over $180M since 2016. This vote of confidence from mission-aligned VCs like Gates Frontier's Dementia Discovery Fund validates Cerevance's approach ahead of Phase 3 readout. It reflects sector conviction in novel targets over traditional models.
Neurodegenerative Market Scales Rapidly
The neurodegenerative therapeutics market stands at $46.7B with an 8.7% CAGR per Prophecy Market Insights. Parkinson's therapeutics specifically project growth from $7.49B in 2026 to $14.28B by 2035 at 7.3% CAGR, driven by aging populations per Precedence Research.
Non-Dopamine Shift Reshapes Landscape
Competitors pursue varied mechanisms: UCB/Novartis advances minzasolmin for OFF time, while AbbVie/Cerevel's tavapadon delays levodopa needs. Cerevance differentiates with NETSseq-derived neuron-enriched targets, avoiding glia-focused or animal model pitfalls. Recent Merck collaboration milestones for Alzheimer's targets, worth up to $1.1B, bolster its multi-asset strategy.
Phase 3 Readout Looms Large
With ARISE enrollment complete, Cerevance anticipates topline results by end of Q3 2026. The $20M extends cash runway to mid-2027, funding through data readout and beyond. Collaborations with Takeda and Merck provide additional validation as pipeline assets advance.